Pituitary tumours: All silent on the epigenetics front

Journal of Molecular Endocrinology

Volumn 42, Issue 6, 2009, Pages 461-468

  Dudley, K J ^a   Revill, K ^a   Clayton, R N ^a   Farrell, W E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE; IKAROS TRANSCRIPTION FACTOR; MATERNALLY EXPRESSED GENE 3; MELANOMA ANTIGEN 3; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; CHROMATID ABERRATION; CPG ISLAND; DISEASE COURSE; DNA CROSS LINKING; DNA HISTONE INTERACTION; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENOME ANALYSIS; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN MODIFICATION; REVIEW; SPORADIC PITUITARY TUMOR; TUMOR SUPPRESSOR GENE;

ADENOMA; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; PITUITARY NEOPLASMS;

EID: 67649446323     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0009     Document Type: Review

References (44)

1. Abbass SAA, Asa SL & Ezzat S 1997 Altered expression of fibroblast growth factor receptor in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 82 1160-1166.
2. Asa SL & Ezzat S 2002 The pathogenesis of pituitary tumors. Nature Reviews. Cancer 2 836-849.
3. Asa SL & Ezzat S 2005 Genetics and proteomics of pituitary tumors. Endocrine 28 43-47.
4. Bahar A, Bicknell JE, Simpson DJ, Clayton RN & Farrell WE 2004a Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23 936-944.
5. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN & Farrell WE 2004b Isolation and characterization of a novel pituitary tumor apoptosis gene. Molecular Endocrinology 18 1827-1839.
6. Burgers WA, Fuks F & Kouzarides T 2002 DNA methyltransferase get connected to chromatin. Trends in Genetics 18 275-277.
7. Dudley KJ, Revill K, Whitby P, Clayton RN & Farrell WE 2008 Genome wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Molecular Cancer Research 6 1567-1574.
8. Esteller M 2007 Epigenetic gene silencing in cancer: the DNA hypermethylome. Human Molecular Genetics 16 R50-R59.
9. Ezzat S & Asa SL 2008 The emerging role of the Ikaros stem cell factor in the neuroendocrine system. Journal of Molecular Endocrinology 41 45-51.
10. Ezzat S, Yu S & Asa SL 2003 Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4 promoter. American Journal of Pathology 163 1177-1184.
11. Ezzat S, Mader R, Yu S, Ning T, Poussier P & Asa SL 2005a Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation 115 1021-1029.
12. Ezzat S, Yu S & Asa SL 2005b The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Molecular Endocrinology 19 1004-1011.
13. Ezzat S, Zhu X, Loeper S, Fischer S & Asa SL 2006 Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Molecular Endocrinology 20 2976-2986.
14. Farrell WE 2005 Epigenetic mechanisms of tumorigenesis. Hormones Metabolism Research 37 361-368.
15. Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z et al. 2006 Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Research 66 6665-6674.
16. Frost SJ, Simpson DJ, Clayton RN & Farrell WE 1999 Transfection of an inducible p16/CDKN2A construct mediated reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Molecular Endocrinology 13 1801-1810.
17. Futscher BW, Oshiro RJ, Wozniak N, Holtan CL, Hanigan H & Domann FE 2002 Role of DNA methylation in the control of cell type specific mapsin expression. Nature Genetics 31 175-179.
18. Gardiner-Garden M & Frommer M 1987 CpG islands in vertebrate genomes. Journal of Molecular Biology 196 261-282.
19. Gonzalgo ML, Liang G, Spruck CH, Zingg JM, RideoutWH & Jones PA 1997 Identification and characterisation of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Research 57 594-599.
20. Heaney AP & Melmed S 2004 Molecular targets in pituitary tumours. Nature Reviews. Cancer 4 285-295.
21. Hoffman BG & Jones SJM 2009 Genome-wide identification of DNA-protein interaction using chromatin immunoprecipitation coupled with flow cell sequencing. Journal of Endocrinology 201 1-13.
22. Jaenish R & Bird A 2003 Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genetics 33 245-254.
23. Jenuwein T & Allis CD 2001 Translating the histone code. Science 293 1074-1080.
24. Kovacs K & Hovarth E 1987 Pathology of pituitary tumors. Endocrinology and Metabolism Clinics of North America 16 529-551.
25. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L 1989 GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenyl cyclase in human pituitary tumors. Nature 340 692-696.
26. Liang G, Gonzales FA, Jones PA, Orntoft TF & Thykjaer T 2002 Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Research 62 961-966.
27. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T & Baylin SB 2006 Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Research 66 3541-3549.
28. Melmed S 2003 Mechanisms of pituitary tumorigenesis: the plastic pituitary. Journal of Clinical Investigation 112 1603-1618.
29. Pernicone PJ, Scheithauer B, Sebo TJ, Kovaks KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BH & Schoene WC 1997 Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79 804-812.
30. Siegfried Z & Cedar H 1997 DNA methylation: a molecular lock. Current Biology 7 R305-R307.
31. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN & Farrell WE 1999 Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes and Cancer 24 328-336.
32. Simpson DJ, McNicol AM, Murray DC, Bahar A, Turner HE, Wass JAH, Esiri MM, Clayton RN & Farrell WE 2004 Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clinical Cancer Research 10 1780-1788.
33. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG & Baylin SB 2002 A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics 31 141-149.
34. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET & Yu Q 2007 Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes and Development 21 1050-1063.
35. Turner BM 2000 Histone acetylation and an epigenetic code. BioEssays 22 836-845.
36. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL & Schubeler D 2005 Chromosome-wide and promoter-specific analyses identify sites of differential methylation in normal and transformed human cells. Nature Genetics 37 853-862.
37. Woloschak M, Yu A & Post KD 1997 Frequent inactivation of the p16 gene in human pituitary tumours by gene methylation. Molecular Carcinogenesis 19 221-224.
38. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A 2002 Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 87 1262-1267.
39. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR & Klibanski A 2003 A pituitary derived MEG3 isoform functions as a growth suppressor in tumor cells. Journal of Clinical Endocrinology and Metabolism 88 5119-5126.
40. Zhao J, Dahle D, Zhou Y, Zhang X & Klibanski A 2005 Hypermethylation of the promoter region is associated with the loss of Meg3 gene expression in human pituitary tumours. Journal of Clinical Endocrinology and Metabolism 90 2179-2186.
41. Zhu X, Asa SL & Ezzat S 2007a Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary. Molecular Endocrinology 21 2005-2015.
42. Zhu X, Lee K, Asa SL & Ezzat S 2007b Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. American Journal of Pathology 170 1618-1628.
43. Zhu X, Asa SL & Ezzat S 2008a Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical Cancer Research 14 1984-1996.
44. Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S & Asa SL 2008b Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. Journal of Clinical Endocrinology and Metabolism 93 3610-3617.